Please login to the form below

Not currently logged in
Email:
Password:

Eisai acquires MGI Pharma for USD 3.9bn

Eisai will buy US-based biotech MGI Pharma for USD 3.9bn in cash, in an effort to bolster its cancer drug business

Japan-headquartered Eisai has revealed it will buy US-based biotech MGI Pharma for USD 3.9bn in cash, in an effort to bolster its cancer drug business.

MGI Pharma is being acquired for USD 41 a share, a 23 per cent premium to its closing price of USD 33.45 on 7 December 2007.

With a focus on cancer, MGI Pharma has three marketed products: Dacogen (decitabine) for myelodysplastic syndrome; Gliadel wafers (polifeprosan 20 with carmustine implant) for the treatment of brain cancers; and the injectable, chemotherapy anti-nausea drug Aloxi (palonosetron).

Eisai's best-selling drug is the Alzheimer's disease product Aricept (donepezil), but like other companies it is facing declining revenues as patents for key products are due to run out by 2010. By acquiring a biotech, Eisai should be able to add novel products to its flagging pipeline.

According to media reports, Eisai will absorb MGI Pharma into its existing US-based oncology business. In 2006, Eisai bought four cancer drugs from Ligand Pharmaceuticals for a total of USD 205m, while in early 2007 the company spent USD 325m on the buy up of Morphotek.

Eisai expects the acquisition of MGI Pharma to complete in Q1 2008. It added that the transaction should be accretive to cash earnings per share in FY08, as well as GAAP earnings in FY09.

Eisai is a mid-sized pharmaceutical company, compared with giants such as Pfizer and GlaxoSmithKline (GSK). It has escaped the confines of the Japanese pharmaceutical market and now has multinational operations.

10th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics